Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime |
Transaction Date |
Type | Company Symbol |
Filed By Symbol |
Shares Owned % Owned |
Shares Vs. Prev Report | View |
| 2025-04-17 09:35 am Sale |
2025-03-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
BLACKROCK INC BLK |
17,483,490 8.400% |
-3,558,982 (-16.91%) |
Filing History |
| 2024-11-07 10:52 am Purchase |
2024-10-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
The Vanguard Group | 20,730,939 10.020% |
424,343 (+2.09%) |
Filing History |
| 2024-11-07 10:25 am Unchanged |
2024-09-30 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
The Vanguard Group | 20,306,596 9.810% |
0 (Unchanged) |
Filing History |
| 2024-11-04 11:18 am Purchase |
2024-09-30 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
The Vanguard Group | 20,306,596 9.810% |
2,542,876 (+14.31%) |
Filing History |
| 2024-10-17 11:52 am Sale |
2024-09-30 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
STATE STREET CORP STT |
8,849,588 4.300% |
-3,927,415 (-30.74%) |
Filing History |
| 2024-09-10 12:09 pm Purchase |
2024-08-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
BLACKROCK INC BLK |
21,042,472 10.200% |
2,361,102 (+12.64%) |
Filing History |
| 2024-02-14 4:21 pm Sale |
2023-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
Baker Bros. Advisors LP | 10,204,089 4.980% |
-8,980,705 (-46.81%) |
Filing History |
| 2024-02-14 09:02 am Purchase |
2023-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
AVORO CAPITAL ADVISORS LLC | 13,050,000 6.400% |
13,050,000 (New Position) |
Filing History |
| 2024-02-13 5:00 pm Purchase |
2023-12-29 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
The Vanguard Group | 17,763,720 8.670% |
3,559,325 (+25.06%) |
Filing History |
| 2024-01-24 5:23 pm Purchase |
2023-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
BLACKROCK INC BLK |
18,681,370 9.100% |
3,762,415 (+25.22%) |
Filing History |
| 2024-01-24 1:06 pm Purchase |
2023-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
STATE STREET CORP STT |
12,777,003 6.240% |
1,650,142 (+14.83%) |
Filing History |
| 2023-02-14 4:00 pm Purchase |
2022-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
Baker Bros. Advisors LP | 19,184,794 9.950% |
720,050 (+3.90%) |
Filing History |
| 2023-02-09 11:12 am Purchase |
2022-12-30 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
The Vanguard Group | 14,204,395 7.620% |
4,791,490 (+50.90%) |
Filing History |
| 2023-02-06 09:33 am Purchase |
2022-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
STATE STREET CORP STT |
11,126,861 5.970% |
2,877,832 (+34.89%) |
Filing History |
| 2023-02-03 4:27 pm Purchase |
2022-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
BLACKROCK INC BLK |
14,918,955 8.000% |
131,560 (+0.89%) |
Filing History |
| 2022-02-14 4:15 pm Purchase |
2021-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
Baker Bros. Advisors LP | 18,464,744 9.950% |
285,863 (+1.57%) |
Filing History |
| 2022-02-09 3:33 pm Sale |
2021-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
The Vanguard Group | 9,412,905 5.230% |
-2,186,429 (-18.85%) |
Filing History |
| 2022-02-09 11:33 am Purchase |
2021-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
STATE STREET CORP STT |
8,249,029 4.580% |
940,213 (+12.86%) |
Filing History |
| 2022-02-01 5:08 pm Sale |
2021-12-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
BLACKROCK INC BLK |
14,787,395 8.200% |
-1,472,350 (-9.06%) |
Filing History |
| 2021-04-12 09:36 am Sale |
2021-03-31 | 13G | BioCryst Pharmaceuticals, Inc. BCRX |
STATE STREET CORP STT |
7,308,816 4.130% |
-3,748,163 (-33.90%) |
Filing History |